Investor Relations

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases.
‍
Spero’s lead product candidate is SPR720, a novel oral therapy for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. 

Spero also has tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), designed to be the first broad-spectrum oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. 

Additionally, Spero has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.